Anebulo Pharmaceuticals Valuation Multiples

Anebulo Pharmaceuticals Overview

About Anebulo Pharmaceuticals

Anebulo Pharmaceuticals Inc is a clinical-stage biotechnology company focused on developing treatments for cannabinoid overdose and substance addiction. Its principal product candidate, ANEB-001 (Selonabant), is designed to rapidly counteract the negative effects of cannabis toxicity, including unintentional cannabis poisoning and acute cannabinoid intoxication. The company is focusing on addressing the unmet medical needs in the treatment of cannabinoid toxicity through various therapies. Anebulo Pharmaceuticals operates in one segment, exclusively in the United States.

Founded

2020

HQ

Employees

3

Website

anebulo.com

Sectors

BiopharmaceuticalsBioTechCannaTechViceTech

Financials (FY)

Revenue: —

EBITDA: ($8M)

EV

$9M

Valuation Multiples

Multiples.vc

Start free trial

Anebulo Pharmaceuticals Financials

Anebulo Pharmaceuticals reported last fiscal year revenue of — and negative EBITDA of ($8M).

In the same fiscal year, Anebulo Pharmaceuticals generated ($8M) in EBITDA losses and had net loss of ($8M).

Anebulo Pharmaceuticals P&L

In the most recent fiscal year, Anebulo Pharmaceuticals reported revenue of — and EBITDA of ($8M).

Anebulo Pharmaceuticals expects next 12-month revenue of XXX and NTM EBITDA of XXX

Anebulo Pharmaceuticals Stock Performance

Anebulo Pharmaceuticals has current market cap of $18M, and enterprise value of $9M.

Anebulo Pharmaceuticals' stock price is $0.44.

Anebulo Pharmaceuticals Valuation Multiples

Anebulo Pharmaceuticals trades at (1.1x) EV/EBITDA.

Anebulo Pharmaceuticals Financial Valuation Multiples

As of April 18, 2026, Anebulo Pharmaceuticals has market cap of $18M and EV of $9M.

Equity research analysts estimate Anebulo Pharmaceuticals' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

Anebulo Pharmaceuticals has a P/E ratio of (2.1x).

Anebulo Pharmaceuticals Margins & Growth Rates

Anebulo Pharmaceuticals' revenue in the last fiscal year grew by —.

Anebulo Pharmaceuticals' revenue per employee in the last FY averaged $0.0M, while opex per employee averaged $2.8M for the same period.

Anebulo Pharmaceuticals Public Comps

See public comps and valuation multiples for other Biopharmaceuticals comps.

Anebulo Pharmaceuticals M&A Activity

Anebulo Pharmaceuticals acquired XXX companies to date.

Last acquisition by Anebulo Pharmaceuticals was on XXXXXXXX, XXXXX. Anebulo Pharmaceuticals acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).

Anebulo Pharmaceuticals Investment Activity

Anebulo Pharmaceuticals invested in XXX companies to date.

Anebulo Pharmaceuticals made its latest investment on XXXXXXXX, XXXXX. Anebulo Pharmaceuticals invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).